SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. - Wikidata - wikimedia - TriplyDB

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

http://www.wikidata.org/entity/Q35181821

about

Glucagon and heart in type 2 diabetes: new perspectives Options for empagliflozin in combination therapy in type 2 diabetes mellitus Diabetes Drugs and Cardiovascular Safety Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Diabetic cardiomyopathy: where we are and where we are going.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Short commentary on empagliflozin and its potential clinical impact Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach.Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.

P2860

Q26738580-B1B19EFF-C61A-4D3A-B1BC-2D9F12BC84A1 Q26745771-00E6B197-ADB2-4A8B-84BA-A4DA2B6ECDDB Q26746085-42CE6863-0321-468F-B362-A2B71A01DCA5 Q26749281-533CA96E-215F-4742-A2E4-CDC00338AE5B Q26767260-2B1B4659-153D-46AE-BB07-20CC0DC344C5 Q26767263-A0D14781-4B8C-4F96-A936-49DCE3548A8B Q26775037-00F80E8D-EE8D-4876-A99E-14444D915522 Q26824616-9D269FF5-0E4A-4FD2-8DF8-6069E84C4460 Q28072352-8C8A0D5A-EC51-469A-9A35-9DF52C06A479 Q28075848-EEB746A7-719B-4F85-BA72-7BEAD1264B95 Q28082343-16D9C319-302B-4EFF-8C57-5D9279452C37 Q30250020-3349E4EA-D114-4778-A63D-8FE42DF7BDD9 Q33556240-0DDB65A4-3C6A-4AE2-B2ED-A496A026A006 Q33625207-9BFC998B-5780-407E-8C4E-849BDBA2E994 Q33625568-A4A65C4A-F639-4FDB-B111-4655CDF20CE1 Q33690717-D1083BE8-4F77-421E-85AC-0CC9D3D6712C Q33763305-FA41D932-5502-4052-AF67-EB43DB4DDA67 Q33845734-19345FB1-AED9-482E-A3BB-E2CEB08075D0 Q33871321-88D9C6E1-7349-4848-99E9-A0C63D536AD0 Q35528797-D5DD63C1-6050-42B0-A391-F66C5291C585 Q35932559-6E04275E-F0D9-4321-9D4A-83DB94314045 Q36317577-431944CC-D037-42AA-8AE5-4BA4E6C216D7 Q36327116-56E4804C-8B26-4377-8794-0B86308DDE3D Q36435496-4A0125E0-8A89-4E3C-AF8A-30BA090116ED Q36599869-10F859AF-0086-4B29-9C18-72E85C834CA2 Q36622125-94840B13-4CC3-49AD-8BA2-37580233BAD7 Q36960633-E3FE4EDF-A902-4663-8D92-7B565074AF11 Q37011769-7339DFCA-DBCD-4586-B709-E0CD29796D9F Q37251449-166C242F-03BA-43DD-9029-51DCCFE58DB5 Q37325818-8EF47835-7D48-40A5-BAE0-1B1BFAE33C91 Q37586607-E25A51C4-D930-40BF-809B-AA175E09A8AD Q37588847-2065D845-5F4C-48CD-8F3F-93405B4A7C36 Q37594479-6CAFF669-DD2B-4A33-B0A0-5ED0BF094AF2 Q37661798-0F0DC77E-B34F-4E14-B6E3-57C607F8637B Q38288267-B2CAD9C6-3F6F-4897-89CD-4EC82172635C Q38597063-D5B1BEF2-791B-4EA6-8DE5-2EB00E651656 Q38687258-3D8CB3E1-CF9D-4D90-A3ED-2994AE4016DC Q38783130-3BED811B-0C46-4E04-AD88-9E325BD27F99 Q38783203-9F04B2C6-4971-4312-9C88-6156CC552D5F Q38815498-93652591-4581-4F25-AC0C-56A0C5BCEBE1

P2860

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

http://www.wikidata.org/entity/Q35181821

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@ast

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@en

type

label

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@ast

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@en

prefLabel

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@ast

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@en

P1433

Q35181821-8E0477D1-6399-49A0-8F42-D675C54D903C

P1476

Q35181821-6182397A-71A4-444B-836B-C653917D30EA

P2093

Q35181821-02295C9C-7EB5-4126-B0D2-79DE9CC90AB7

Q35181821-3E5E96D3-6DB9-491A-87AF-57519ABCD09D

Q35181821-418DC6C6-EC97-4EAF-A016-099ED1D42058

Q35181821-7ED9B6FE-3140-4E3F-B8FF-553C728B9506

Q35181821-8DB8A409-2F27-4211-9DB6-6604EA478A42

Q35181821-93860543-6998-4576-8401-B58653AE0C85

Q35181821-AEE6F2FA-16C8-499D-BD17-DFD23657B20C

Q35181821-F2D56F48-501E-4A2A-BFA9-0D223BBB25B7

P275

Q35181821-7B7DE824-A849-443A-A3F6-F1F8C6264F32

P2860

Q35181821-0865FF32-04DA-4664-980F-7B65BC45D12A

Q35181821-0A5B18AD-D572-4D0C-AF56-364E6EA5D420

Q35181821-0DD8A153-C77C-4BE6-A082-49B9153B014A

Q35181821-0ECBAD00-4A8E-4449-8BA5-0B5D8C803130

Q35181821-11572135-4D53-40D1-930A-33BB0A3236A6

Q35181821-1A92C878-231B-4458-BBDA-86DD8D7A2356

Q35181821-1BDDA56C-762E-447F-81BF-CB97B8CA6121

Q35181821-1BEE8A00-06E1-4FDD-A305-BE7F3D7BE867

Q35181821-2CDA2391-6F11-4306-9540-1A4C9A3F1116

Q35181821-2EAD1387-F853-4459-BA00-77A2A92255FA

P304

Q35181821-BE327D05-4561-4906-83B3-0954AC3E398B

P31

Q35181821-1EB356A4-BC75-45DD-B738-A3110172CBA3

Q35181821-54391FBF-C35B-4053-A72A-D6A35A5D9303

P356

Q35181821-DF140676-6692-4A42-96F0-1ED26D9887AC

P407

Q35181821-050C64FF-B98E-4533-874D-EC6942E19998

P433

Q35181821-498121BE-685D-4300-B023-C64924D57576

P478

Q35181821-FE2A9F86-F94E-4528-8DD2-142D66ED79A1

P50

Q35181821-6BB1B77E-97E5-4818-A624-BD98A829FC76

Q35181821-D37E4E46-951A-48B5-B414-F02EBB451A97

P5008

Q35181821-E68404C6-3CA3-47E2-A1F6-3F0C05D6A0AD

P577

Q35181821-2F55A771-71CD-4584-90BE-9B288476A4E7

Q35181821-F6210881-D5DE-44B8-9215-5C67D88D846F

P5875

Q35181821-46060DAC-CDAE-4981-B3A7-7729D810C32E

P698

Q35181821-B96FF8D8-5C1A-4669-95FC-660E244EC42B

P921

Q35181821-21324B93-1D69-4DCC-B15A-C9C0A1CEBCDA

Q35181821-45D00F4C-91E6-4A26-A932-FF14E3766B1F

Q35181821-4B1E1B2F-290E-4C81-BE10-11EAC0ED77F6

Q35181821-86FEF75F-ACEF-4CEC-B900-FACB3AC3FC3F

Q35181821-E9A3F21B-3549-45AA-B5DC-4AFBB383A76D

Q35181821-F787943D-0A50-45FD-8E43-3E7151AFABA2

P932

Q35181821-994C3E8E-8563-4C77-B5A2-A022E1198C8C

P356

1479164114559852

P1433

Diabetes and Vascular Disease Research

P1476

SGLT-2 inhibitors and cardiova ...... iew of ongoing outcome trials.

@en

P2093

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

David Fitchett

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Woerle

http://www.w3.org/2001/XMLSchema#string

Roberto Ferrari

http://www.w3.org/2001/XMLSchema#string

Rosa-Maria Espadero

http://www.w3.org/2001/XMLSchema#string

Silvio E Inzucchi

http://www.w3.org/2001/XMLSchema#string

Stefan Hantel

http://www.w3.org/2001/XMLSchema#string

Uli C Broedl

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Uric acid and risk of heart failure: a systematic review and meta-analysis

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Incorporating lag time to benefit into prevention decisions for older adults

Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

P304

90-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1479164114559852

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Odd Erik Johansen

P5008

P577

2015-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270964571

http://www.w3.org/2001/XMLSchema#string

P698

25589482

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

type-2 diabetes

mechanism of action

cardiovascular disease

genitourinary system

maturity-onset diabetes of the young

P932

4361459

http://www.w3.org/2001/XMLSchema#string